FrancophonIA/ELRC3.0 huggingface dataset:
English: The CVMP was requested to give its opinion on the measures that need to be taken in order to ensure the prudent use of colistin in food-producing animals across the EU and to minimise potential risks with the use of the identified products; inter alia whether there is a need to include adequate indications and warnings on prudent use in the product information and/or restrict indications for the identified products taking into account the CVMP revised guideline on the SPC for antimicrobial products (EMEA/CVMP/SAGAM/383441/2005) 2.
Estonian: Veterinaarravimite komiteel paluti esitada arvamus meetmete kohta, millega tagada kolistiini arukas kasutamine toiduloomadel kogu Euroopa Liidus ja vähendada nimetatud ravimite võimalikke riske; muu hulgas selle kohta, kas ravimiteabesse on vaja lisada asjakohased aruka kasutamise näidustused ja hoiatused ja/või piirata nimetatud ravimite näidustusi, arvestades veterinaarravimite komitee läbivaadatud suuniseid, mis käsitlevad antimikroobsete ravimite omaduste kokkuvõtteid (EMEA/CVMP/SAGAM/383441/2005) 2.
English: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500070670.pdf
Estonian: (EMEA/CVMP/SAGAM/383441/2005) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500070670.pdf
English: Oral colistin formulations including powder, solution, premix, tablets and paste have been authorised, mainly for group and flock treatment for the treatment and prevention of different specified gastrointestinal diseases caused by sensitive Enterobacteriacea species (e.g. Salmonella and Escherichia coli), but marketing authorisations without more specific indications do also exist.
Estonian: Kolistiini sisaldavad suukaudsed ravimvormid, sealhulgas pulber, lahus, eelsegu, tabletid ja pasta, on heaks kiidetud peamiselt imetajaja linnurühmade ravis kolistiini suhtes tundlike enterobakteriliikide (nt Salmonella ja Escherichia coli) põhjustatud mitmesuguste konkreetsete seedetrakti infektsioonide raviks ja ennetamiseks, kuid samuti on olemas konkreetsemate näidustusteta müügilube.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amendments in the summaries of product characteristics, labelling and package leaflets in Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning ravimi omaduste kokkuvõtete, märgistuse ja pakendi infolehtede muudatused III lisas.
English: Therefore, on 11 December 2014 the Committee adopted by consensus a positive opinion, recommending variations to the terms of the marketing authorisations for veterinary medicinal products containing colistin to be administered orally.
Estonian: Seetõttu võttis veterinaarravimite komitee 11. detsembril 2014 ühehäälselt vastu positiivse arvamuse, soovitades muuta kolistiini sisaldavate suukaudsete veterinaarravimite müügilubade tingimusi.
English: Based on the evaluation of the currently available data, the CVMP considered that the overall benefitrisk profile for these products remains positive subject to amendments in the product information.
Estonian: Olemasolevate andmete hindamise alusel järeldas veterinaarravimite komitee, et nende ravimite üldine kasulikkuse ja riski profiil on endiselt positiivne, kuid ravimiteavet tuleb muuta.
English: No written comments on the recommendations and proposed changes in the product information were provided by the applicants and marketing authorisation holders.
Estonian: Taotlejad ja müügiloa hoidjad ei esitanud soovituste ja ravimiteabe kavandatavate muudatuste kohta kirjalikke märkusi.
English: Committee for Medicinal Products for Veterinary Use (CVMP)
Estonian: Veterinaarravimite komitee
English: Colistin sulfate belongs to the polymyxin group of antibiotics.
Estonian: Kolistiinsulfaat on polümüksiinide rühma kuuluv antibiootikum.
English: On 12 May 2014, the European Commission presented to the Agency a referral notification under Article 35 of Directive 2011/82/EC, regarding veterinary medicinal products containing colistin to be administered orally.
Estonian: Euroopa Komisjon tegi 12. mail 2014 Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 35 kohase esildise kolistiini sisaldavate suukaudsete veterinaarravimite kohta.
English: Opinion following an Article 351 referral for veterinary medicinal products containing colistin to be administered orally
Estonian: Arvamus pärast artikli 35 kohast esildist kolistiini sisaldavate suukaudsete veterinaarravimite kohta
English: 1 Article 35 of Directive 2001/82/EC, as amended 2 CVMP revised guideline on the SPC for antimicrobial products (EMEA/CVMP/SAGAM/383441/2005)
Estonian: Muudetud direktiivi 2001/82/EÜ artikkel 35 2 Mikroobivastaste ravimite omaduste kokkuvõtet käsitlevad veterinaarravimite komitee läbivaadatud suunised
English: MA (EU) number (Invented) name Strength Pharmaceutical form Route of administration
Estonian: (Väljamõeldud) nimetus
English: l t o r d
Estonian: l n a d
English: AS03 adjuvant composed of squalene (10.69 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)
Estonian: Adjuvant AS03 sisaldab skvaleeni (10,69 milligrammi), DL-α-tokoferooli (11,86 milligrammi) ja polüsorbaat 80 (4,86 milligrammi)
English: Strength Pharmaceutical Form
Estonian: TugevusRavimvorm Manustamistee
English: Packaging Content (concentration) Package size
Estonian: Pakendi iseloomustus Pakendi sisu Pakendi suurus
English: suspension: 2.5 ml; emulsion: 2.5 ml
Estonian: susepensioon: 2.5 ml emulsion: 2,5 ml
English: Intramuscular use suspension (H1N1): vial (glass); emulsion (adjuvant): vial (glass)
Estonian: Intramuskulaarne susepensioon (H1N1): viaal (klaas); emulsioon (adjuvant): viaal (klaas)
English: 2 x 25 vials (emulsion)
Estonian: 50 viaali (suspension) + 2 x 25 viaali (emulsion)
English: Split influenza virus inactivated, containing antigen* equivalent to:
Estonian: Inaktiveeritud purustatud gripiviirus, mille antigeeni* sisaldus on ekvivalentne: A/California/7/2009 (H1N1)v-sarnane viirus
English: Cufence should be taken on an empty stomach, at least one hour before or two hours after meals.
Estonian: Cufencet tuleb võtta tühja kõhuga vähemalt üks tund enne või kaks tundi pärast sööki.
English: What measures are being taken to ensure the safe and effective use of Cufence?
Estonian: Mis meetmed võetakse, et tagada Cufence ohutu ja efektiivne kasutamine?
English: Cufence must be stored in a refrigerator (between 2ºC and 8ºC).
Estonian: Cufencet tuleb hoida külmikus (2-8 °C).
English: Further information on Cufence can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/cufence
Estonian: Lisateave Cufence kohta on ameti veebilehel: www.ema.europa.eu/medicines/human/EPAR/cufence.
English: The European Medicines Agency therefore decided that Cufence's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seepärast otsustas Euroopa Ravimiamet, et Cufence kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Other information about Cufence
Estonian: Muu teave Cufence kohta
English: What is Cufence and what is it used for?
Estonian: Mis on Cufence ja milleks seda kasutatakse?
English: The recommended daily dose is 4 to 8 capsules in adults, and 2 to 5 capsules in children.
Estonian: Soovitatav ööpäevane annus on 4-8 kapslit täiskasvanutel ja 2-5 kapslit lastel.
English: As for all medicines, data on the use of Cufence are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Cufence kasutamise kohta pidevat järelevalvet.
English: Skin rash may affect up to 1 in 100 people.
Estonian: Nahalöövet võib esineda kuni 1 inimesel 100st.
English: Side effects reported with Cufence are carefully evaluated and any necessary action taken to protect patients.
Estonian: Cufence kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Cufence is available as 200 mg capsules.
Estonian: Cufencet turustatakse 200 mg kapslitena.
English: Why is Cufence authorised in the EU?
Estonian: Miks Cufence ELis heaks kiideti?
English: The safety of Cufence has been shown to be similar to that of other trientine medicines.
Estonian: Cufence ohutus sarnaneb teiste trientiinravimite ohutusega.
English: A small proportion of patients had deteriorating symptoms: 5% with worsening liver symptoms and 3% with worsening neurological symptoms.
Estonian: Väikesel arvul patsientidest sümptomid halvenesid: 5%-l halvenesid maksasümptomid ja 3%-l neuroloogilised sümptomid.
English: What are the risks associated with Cufence?
Estonian: Mis riskid Cufencega kaasnevad?
English: Cufence (trientine dihydrochloride) EMA/410631/2019
Estonian: Cufence (trientiindihüdrokloriid) EMA/325626/2019
English: For more information about using Cufence, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Cufence kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cufence have also been included in the summary of product characteristics and the package leaflet.
Estonian: Cufence ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Cufence (trientine dihydrochloride)
Estonian: Cufence (trientiindihüdrokloriid)
English: In some patients, neurological deterioration can occur at the start of the treatment, with symptoms such as dystonia (involuntary muscle contractions), stiffness, tremor (shaking) and dysarthria (difficulty speaking).
Estonian: Mõnel patsiendil võivad esineda ravi algul sellised neuroloogilised häired nagu düstoonia (lihaste tahtmatud kokkutõmbed), jäikus, treemor (värisemine) ja düsartria (hääldamispuue).
English: The most common side effect with Cufence (which may affect up to 1 in 10 people) is nausea (feeling sick), especially when starting treatment.
Estonian: Cufence kõige sagedam kõrvalnäht (võivad esineda kuni 1 patsiendil 10st) on iiveldus, eriti ravi alguses.
English: How is Cufence used?
Estonian: Kuidas Cufencet kasutatakse?
English: Cufence is used in patients who cannot take D-penicillamine, another medicine for this condition.
Estonian: Cufencet kasutatakse patsientidel, kes ei saa võtta D-penitsillamiini (samuti selle haiguse ravim).
English: In a study of medical records of 77 patients treated with trientine for at least six months, symptoms of liver disease improved in almost half (49%) of the patients treated, and neurological symptoms
Estonian: Vähemalt kuus kuud trientiiniga ravitud 77 patsiendi terviseandmete uuringus paranesid maksahaiguse sümptomid ligikaudu pooltel (49%) ravitud patsientidest ja neuroloogilised sümptomid paranesid 14%-l patsientidest.
English: How does Cufence work?
Estonian: Kuidas Cufence toimib?
English: It works by attaching to copper in the body and forming a complex that is then eliminated in the urine and faeces.
Estonian: See seondub organismis vasega, moodustades keemilise kompleksi, mis seejärel eritub uriini ja väljaheitega.
English: Trientine has been used for over 30 years to treat patients with Wilson's disease.
Estonian: Cufencet on kasutatud Wilsoni tõvega patsientide raviks üle 30 aasta.
English: Cufence can only be obtained with a prescription and treatment should be started by a specialist with experience in the management of Wilson's disease.
Estonian: Cufence on retseptiravim ja ravi peab alustama Wilsoni tõve ravis kogenud spetsialist.
English: The capsules are taken in 2 to 4 divided doses.
Estonian: Kapsleid võetakse jagatuna 2-4 annuseks.
English: Cufence contains the active substance trientine dihydrochloride.
Estonian: Cufence sisaldab toimeainena trientiindihüdrokloriidi.
English: The company that markets Cufence will conduct a study to further characterise the effectiveness of trientine in the treatment of Wilson's disease, including its effect on the associated liver, neurological or psychiatric symptoms and what the dose should be during early treatment.
Estonian: Cufence turustaja korraldab uuringu, et paremini iseloomustada trientiini efektiivsust Wilsoni tõve ravis, sealhulgas selle mõju kaasnevatele maksa-, neuroloogilistele ja psühhiaatrilistele sümptomitele, ning täpsustada ravi alguse annust.
English: For the full list of side effects and restrictions of Cufence, see the package leaflet.
Estonian: Cufence kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Although Dpenicillamine is the main treatment for this condition, trientine is effective at improving the symptoms of liver and neurological disease in patients who cannot take this medicine.
Estonian: Ehkki selle haiguse põhiravim on D-penitsillamiin, parandab trientiin maksahaiguse ja neuroloogilisi sümptomeid patsientidel, kes ei saa seda ravimit võtta.
English: Duodenitis (inflammation of the duodenum, the part of the gut leading out of the stomach) and severe colitis (inflammation in the large bowel causing pain and diarrhoea) have also been reported.
Estonian: Teatatud on ka duodeniidist (kaksteistsõrmikupõletik) ja raskest koliidist (valu ja kõhulahtisust põhjustav jämesoolepõletik).
English: The active substance in Cufence, trientine, has been shown to improve symptoms of liver and neurological disease in patients with Wilson's disease who could no longer take D-penicillamine.
Estonian: Cufence toimeaine trientiin vähendab tõendatult neuroloogilise ja maksahaiguse sümptomeid Wilsoni tõvega patsientidel, kes ei saa enam D-penitsillamiini võtta.
English: What benefits of Cufence have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cufence kasulikkus?
English: An overview of Cufence and why it is authorised in the EU
Estonian: Ülevaade ravimist Cufence ja ELis müügiloa väljastamise põhjendus
English: The active substance in Cufence, trientine, is a chelating agent.
Estonian: Cufence toimeaine trientiin on kelaativ aine.
English: Cufence is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage.
Estonian: Wilsoni tõbi on geneetiline haigus, mille korral toidust imendunud vask ladestub organismis, eriti maksas ja ajus, kahjustades organismi.
English: Date of latest renewal: 15 January 2015
Estonian: Müügiloa viimase uuendamise kuupäev: 15. jaanuar 2015
English: OTHER SPECIAL WARNING(S), IF NECESSARY Do not shake.
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) Mitte raputada.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 3 December 2007
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 3. detsember 2007
English: As with all therapeutic proteins, there is potential for immunogenicity.
Estonian: Sarnaselt kõigi raviotstarbeliste valkudega on võimalik immunogeensus.
English: Patients were treated until disease progression or unacceptable toxicity occurred.
Estonian: Patsiente raviti kuni haiguse progresseerumiseni või aktsepteerimatu toksilisuse avaldumiseni.
English: An exploratory analysis showed similar results to those in the previous table.
Estonian: Uurimuslik analüüs näitas sarnaseid tulemusi eelnevas tabelis esitatutega.
English: x1 vial
Estonian: x1 viaal
English: The diluted solution must not be frozen.
Estonian: Lahjendatud lahust ei tohi lasta külmuda.
English: The final concentration should not exceed 10 mg/mL.
Estonian: Lõplik kontsentratsioon ei tohi olla kõrgem kui 10 mg/ml.
English: Other medicines and Vectibix
Estonian: Muud ravimid ja Vectibix
English: 1 Greater than or equal to grade 3 is defined as severe or life-threatening Special populations
Estonian: 1 3. või kõrgem raskusaste on määratletud kui tõsine või eluohtlik Erirühmad
English: Do not administer Vectibix if its appearance is not as described above.
Estonian: Ärge manustage Vectibix'i, kui selle välimus erineb eelnevast kirjeldusest.
English: Please consult your doctor if you are unsure of your RAS tumour status.
Estonian: Konsulteerige palun oma arstiga, kui te ei ole kindel oma kasvaja RAS-staatuse osas.
English: Ulcerative keratitis1,4 Keratitis1
Estonian: Haavandiline keratiit1,4 Keratiit1
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should be no longer than 24 hours at 2°C - 8°C.
Estonian: Kui ravimit ei kasutata kohe, on kõlblikkusaeg ja säilitamistingimused kasutaja vastutusel ega tohiks tavaliselt ületada 24 tundi temperatuuril 2 °C kuni 8 °C.
English: The elimination half-life was approximately 7.5 days (range: 3.6 to 10.9 days).
Estonian: Eliminatsiooni poolväärtusaeg oli ligikaudu 7,5 päeva (vahemikus 3,6...10,9 päeva).
English: Panitumumab + FOLFIRI Wild-type RAS (n = 69)
Estonian: Panitumumab + FOLFIRI Metsikut tüüpi RAS (n = 69)
English: Do not shake or vigorously agitate the vial.
Estonian: Ärge raputage ega loksutage viaali.
English: The detection of antibody formation is dependent on the sensitivity and specificity of the assay.
Estonian: Antikehade moodustumise avastamine sõltub analüüsi tundlikkusest ja spetsiifilisusest.
English: Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud sildil ja karbil pärast „EXP“.
English: Prolonged exposure to the sun can make the rash worse.
Estonian: Pikaajaline päikese käes viibimine võib halvendada lööbe kulgu.
English: Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC08
Estonian: Farmakoterapeutiline rühm: Kasvajavastased ained, monoklonaalsed antikehad, ATC-kood: L01XC08
English: • Compared with patients who did not develop antibodies, no relationship between the presence of anti-panitumumab antibodies and pharmacokinetics, efficacy and safety has been observed.
Estonian: • võrreldes patsientidega, kel antikehi ei moodustunud, ei täheldatud mingit seost panitumumabivastaste antikehade olemasolu ning ravimi farmakokineetika, efektiivsuse ja ohutuse vahel.
English: Stevens-Johnson syndrome4
Estonian: Stevensi-Johnsoni sündroom4
English: When growth factors (other body proteins) attach to the EGFR, the cancer cell is stimulated to grow and divide.
Estonian: Kui kasvufaktorid (teised organismi valgud) kinnituvad EGFR-ile, stimuleeritakse vähirakk kasvama ja jagunema.
English: The recommended infusion time is approximately 60 minutes.
Estonian: Soovitatav infusiooniaeg on ligikaudu 60 minutit.
English: Response rate (investigator assessed)a (95% CI) Stable Disease PFS
Estonian: Ravivastuse määr (uurija hinnang)a (95% CI) Stabiilne haigus PFS
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/423/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/07/423/001
English: There was no difference in overall survival (OS) seen in either group.
Estonian: Üldine elulemus (OS, ingl overall survival) kummaski rühmas ei erinenud.
English: Patients should be informed of the possibility of a late onset reaction and instructed to contact their physician if symptoms of a hypersensitivity reaction occur.
Estonian: Patsiente tuleb hoiatada hilisreaktsioonide tekke võimalusest ja instrueerida neid arstiga ühendust võtma, kui ilmnevad ülitundlikkusreaktsiooni sümptomid.
English: It is important to tell your doctor if you are pregnant; think you may be pregnant; or plan to get pregnant.
Estonian: Palun rääkige oma arstile, kui te olete rase, kahtlustate endal rasedust või plaanite rasestuda.
English: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal medicines.
Estonian: Teatage oma arstile või apteekrile, kui te võtate või olete hiljuti võtnud või kavatsete võtta mistahes muid ravimeid, sh käsimüügiravimid ja taimsed ravimid.
English: Vectibix may have a minor influence on the ability to drive and use machines.
Estonian: Vectibix võib kergelt mõjutada autojuhtimise ja masinate käsitsemise võimet.
English: Other electrolyte disturbances, including hypokalaemia, have also been observed.
Estonian: Täheldatud on ka teisi elektrolüütide häireid, kaasa arvatud hüpokaleemiat.
English: The major study objective was comparison of PFS in the oxaliplatin cohort.
Estonian: Uuringu peamine eesmärk oli PFS võrdlus oksaliplatiini kohordis.
English: No new toxicities or worsening of previously recognised toxicities beyond the expected additive effects were observed.
Estonian: Ei täheldatud uusi toksilisi toimeid või varasemalt teada olnud toksiliste toimete süvenemist üle ootuspärase aditiivse toime.
English: See section 2 “Vectibix contains sodium”.
Estonian: Vt lõik 2 „Vectibix sisaldab naatriumi“.
English: The product should be used immediately after dilution.
Estonian: Ravim tuleb pärast lahjendamist kohe ära kasutada.
English: KRAS and NRAS genes encode small, GTP-binding proteins involved in signal transduction.
Estonian: KRAS ja NRAS geenid kodeerivad väikseid, GTP-ga seonduvaid valke, mis osalevad signaali ülekandes.
English: This is equivalent to 0.017% of the recommended maximum daily dietary intake of sodium for an adult.
Estonian: See on võrdne 0,017%-ga naatriumi maksimaalsest soovitatud ööpäevasest toiduga saadavast kogusest täiskasvanutel.
English: Patients may be advised to apply moisturiser and sunscreen to face, hands, feet, neck, back and chest every morning during treatment, and to apply the topical steroid to face, hands, feet, neck, back and chest every night during treatment.
Estonian: Patsientidele võib soovitada kanda niisutavat ja päikesekaitsevahendit näole, kätele, jalgadele, kaelale, seljale ja rindkerele igal hommikul ravi ajal ning paikset steroidkreemi näole, kätele, jalgadele, kaelale, seljale ja rindkerele igal õhtul ravi ajal.
English: The fatal event occurred after re-exposure following a prior episode of angioedema; both episodes occurred greater than 24 hours after administration (see sections 4.3 and 4.4).
Estonian: Surmaga lõppenud juht ilmnes pärast taasmanustamist eelneva angioödeemi episoodi järgselt; mõlemad episoodid tekkisid hiljem kui 24 tundi pärast manustamist (vt lõigud 4.3 ja 4.4).
English: There have been reports of overdose at doses up to approximately twice the recommended therapeutic dose (12 mg/kg).
Estonian: Üleannustamist on registreeritud ligikaudu kuni kahekordsete soovituslike terapeutiliste annuste puhul (12 mg/kg).
English: During or following treatment you may experience an infusion reaction.
Estonian: Järgneva ravi ajal võib teil esineda infusioonireaktsioon.
English: • if you are allergic to panitumumab or any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui olete panitumumabi või selle ravimi mistahes koostisosade (loetletud lõigus 6) suhtes allergiline;
English: When prepared according to the instructions given in section 6.6, the final panitumumab concentration should not exceed 10 mg/mL.
Estonian: Valmistatuna vastavalt lõigus 6.6 antud juhistele, ei ületa panitumumabi lõplik kontsentratsioon 10 mg/ml.
English: However, at doses above 2 mg/kg, the AUC of panitumumab increases in an approximately dose-proportional manner.
Estonian: Üle 2 mg/kg annuste korral suureneb panitumumabi AUC ligikaudu annusega proportsionaalselt.
English: EGFR has been implicated in the control of prenatal development and may be essential for normal organogenesis, proliferation, and differentiation in the developing embryo.
Estonian: EGFR osaleb prenataalse arengu reguleerimises ja võib omada tähtsust normaalses organogeneesis, proliferatsioonis ja areneva loote diferentseerumises.
English: Do not use Vectibix:
Estonian: Ärge kasutage Vectibix'i:
English: The maximum frequency estimated from the upper limit of 95% confidence interval for the point estimate, i.e., 3/2,224 (or 0.13%).
Estonian: Punkthinnangu 95% usaldusvahemiku ülemise piirväärtuse alusel hinnatud maksimaalne sagedus, st 3/2224 (ehk 0,13%).